Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs

A group of familiar faces to Incyte watchers has broken off to start their own biotech, pulling in $102 million to develop competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and Pfizer.